The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial also includes an arm for targeting tumors with non-p.V600E BRAF mutations with trametinib (https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match, accessed 1/19/2017). Here, BRAF is linked to cancer.